Rubicon Research

Rubicon Research (Rubicon Research Pvt. Ltd.) is a contract research and a Drug delivery company Located in Mumbai, India. In formulation development, Rubicon has a presence in all therapeutic areas excluding cytotoxic drugs, beta-lactum antibiotics and steroids. Private Equity firm Everstone Group has invested in Rubicon Research.[1]

Rubicon Research Pvt. Ltd.
Private Limited company
IndustryPharmaceutical
FoundedMumbai, India 1999
Headquarters
Mumbai, India
,
India
ProductsPharmaceuticals
ServicesContract Research, Formulation Development (NDDS), Contract Manufacturing & supply chain, Dossier Development ANDA/CTD format
Number of employees
200 (2010)
Websitewww.rubicon.co.in

History

Rubicon Research was founded by Ms. Pratibha Pilgaonkar (CEO), Mr. Sudhir Pilgaonkar (CFO) and Ms. Maharukh Rustomjee(COO) in the year 1999. Rubicon Research started its operations in contract research primarily in the R & D center located in Bhandup, Mumbai with three scientists in a 2,000 sq ft (190 m2) laboratory in 2000.

In 2003, the Directorate of Science and Technology, Government of India approved the facilities as a commercial Research and Development (R&D) company.

In 2006-07 Rubicon licensed its Orodispersible excipient, RubiODT to Mallinckrodt Baker, Inc.[2]

Corporate structure

[3]

  • Ms. Pratibha Pilgaonkar (Chief Executive Officer)
  • Mr. Sudhir Pilgaonkar (Co-Founder and Chief Commercial Officer)
  • Dr. L.S. Rao (Chief Scientific Officer)

Recent news

Ms. Pratibha Pilgaonkar, CEO and Director of Rubicon Research Pvt Ltd. Mumbai, India was invited as Chief guest at AAiPS 2010 to speak about ‘Pharmaceutical Research and Development - Opportunities in India’ [4]

Rubicon Research has a cGMP commercial production facility at Ambernath. Rubicon Research has started its commercial manufacturing and shipments to US & Europe since Sep 2015 Rubicon Research was audited by USFDA in March 2015 & Dec 2015, both time they were having Zero 483

References
  1. "Everstone buys Mumbai-based drug tech firm Rubicon for Rs 220-crore". The Economic Times. Retrieved 3 March 2017.
  2. Pharmaceutical online : Mallinckrodt Baker And Rubicon Research Sign Agreement For Performance Excipient Development
  3. Bloomsberg Businessweek: Rubicon Research Private Limited
  4. American association of Indian Pharmaceutical Scientists
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.